

Human EGFR / HER1 / ErbB1 Protein (His & AVI Tag), Biotinylated

Catalog Number: 10001-H27H-B



Sino Biological
Biological Solution Specialist

General Information

Gene Name Synonym:

ERBB; ERBB1; HER1; mENA; NISBD2; PIG61

Protein Construction:

A DNA sequence encoding the human EGFR (NP_005219.2) (Met1-Ser645) was expressed with a c-terminal polyhistidine tagged AVI tag at the C-terminus. The expressed protein was biotinylated in vivo by the Biotin-Protein ligase (BirA enzyme) which is co-expressed.

Source: Human

Expression Host: Human Cells

QC Testing

Biotin/Protein Ratio:

0.7-1 as determined by the HABA assay.

Purity: > 95 % as determined by SDS-PAGE.

Endotoxin:

<1.0 EU per µg protein as determined by the LAL method.

Stability:

Samples are stable for up to twelve months from date of receipt at -70 °C

Predicted N terminal: Leu 25

Molecular Mass:

The recombinant human EGFR consists of 647 amino acids and predicts a molecular mass of 71.9 kDa.

Formulation:

Lyophilized from sterile PBS, pH 7.4.

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Storage:


Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:

Detailed reconstitution instructions are sent along with the products.

SDS-PAGE:



Protein Description

As a member of the epidermal growth factor receptor (EGFR) family, EGFR protein is type I transmembrane glycoprotein that binds a subset of EGF family ligands including EGF, amphiregulin, TGF- α , betacellulin, etc. EGFR protein plays a crucial role in signaling pathway in the regulation of cell proliferation, survival and differentiation. Binding of a ligand induces EGFR protein homo- or heterodimerization, the subsequent tyrosine autophosphorylation and initiates various down stream pathways (MAPK, PI3K/PKB and STAT). In addition, EGFR signaling also has been shown to exert action on carcinogenesis and disease progression, and thus EGFR protein is proposed as a target for cancer therapy currently.

References

1.Schlessinger, J. (2000) Cell signaling by receptor tyrosine kinases. *Cell* 103(2): 211-25. 2.Giaccone, G. (2005) HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy. *Ann. Oncol.* 16(4): 538-48. 3.Yarden, Y., *et al.* (2001) Untangling the ErbB signalling network. *Nat. Rev. Mol. Cell. Biol.* 2(2): 127-37.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Tel: +86-400-890-9989 (Global), +1-215-583-7898 (USA), +49(0)6196 9678656 (Europe)

Website: <http://www.sinobiological.com>